Managing GERD during pregnancy requires careful selection of acid-suppressing therapy, as the safety profile of each option in the context of pregnancy must be weighed.
Approximately two-thirds of pregnant women experience heartburn, which can begin in any trimester. GERD in pregnancy is therefore common, and treatment decisions must account for both maternal symptom relief and foetal safety.
The protocol addresses acid-suppressing therapy options with attention to their FDA pregnancy categorisation — including relevant distinctions between specific agents within the available classes. The full selection criteria, sequencing, and complete clinical details are in the protocol.
Approximately two-thirds of pregnant women experience heartburn, which can begin in any trimester.
All histamine H2-blockers are FDA Category B, and all PPIs are FDA Category B except omeprazole, which is FDA Category C.
DOI: 10.14309/ajg.0000000000001538
View source ↗